{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:11:39Z","timestamp":1780618299887,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012204","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T00:00:00Z","timestamp":1494374400000}}],"reference-count":263,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012204.pub2","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T15:56:27Z","timestamp":1494431787000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2017","author":[{"given":"Bianca","family":"Hemmingsen","sequence":"first","affiliation":[{"name":"Herlev University Hospital; Department of Internal Medicine; Herlev Ringvej 75 Herlev Denmark DK-2730"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Sonne","sequence":"additional","affiliation":[{"name":"Gentofte Hospital, University of Copenhagen; Center for Diabetes Research, Department of Medicine; Kildegaardsvej 28 Hellerup Denmark DK-2900"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Richter","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,10]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD012204.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.numecd.2014.06.010","article-title":"Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight\/obese persons with prediabetes","volume":"24","author":"Ariel","year":"2014","journal-title":"Nutrition, Metabolism, and Cardiovascular diseases"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0002|cit2","first-page":"A260","article-title":"Liraglutide for overweight, older individuals with prediabetes","volume":"62","author":"Kim","year":"2013","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD012204.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.2337\/dc13-0354","article-title":"Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes","volume":"36","author":"Kim","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00125-013-3134-3","article-title":"Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study","volume":"57","author":"Kim","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0005|cit5","unstructured":"NCT01784965 Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD clinicaltrials.gov\/ct2\/show\/NCT01784965"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0006|cit6","first-page":"A112","article-title":"Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes","volume":"61","author":"Kelly","year":"2012","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1475-2840-11-64","article-title":"Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial","volume":"11","author":"Kelly","year":"2012","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0008|cit8","unstructured":"NCT00546728 The vascular effects of exenatide versus metformin in patients with pre-diabetes clinicaltrials.gov\/ct2\/show\/NCT00546728"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0009|cit9","unstructured":"Martinez-Abundis E Gonzalez-Heredia T Hernandez-Corona DM Gonzalez-Ortiz M Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance Diabetes 2015 A635 6"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012204.pub2-BIB0010|cit10","first-page":"34","article-title":"Exenatide\/diet vs diet alone for treatment of prediabetes","volume":"60","author":"McLaughlin","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0011|cit11","unstructured":"NCT02084654 Exenatide and weight loss for diabetes prevention clinicaltrials.gov\/ct2\/show\/NCT02084654"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0012|cit12","first-page":"SUN","article-title":"Effect of exenatide on weight and metabolic profile in obese insulin-resistant individuals and results after drug discontinuation","volume":"34","author":"Tam","year":"2013","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0013|cit13","unstructured":"CLAF237A2357 www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/attachment\/2005-002778-30\/1\/17121"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0014|cit14","unstructured":"EudraCT 2005-002778-30 A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-002778-30\/DE"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0015|cit15","unstructured":"NCT00237250 Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance www.clinicaltrials.gov\/ct2\/show\/NCT00237250"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/dc07-1616","article-title":"Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0017|cit17","unstructured":"NCT00500370A Pilot study of effects of exenatide on body weight in non-diabetic, obese patients clinicaltrials.gov\/ct2\/show\/NCT00500370"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0019|cit19","first-page":"A196","article-title":"Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non-diabetic, obese patients","volume":"1","author":"Trautmann","year":"2009","journal-title":"Journal of Diabetes"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0020|cit20","first-page":"42","article-title":"Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56-week randomised, controlled, scale obesity and prediabetes trial","volume":"8","author":"Astrup","year":"2015","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0021|cit21","unstructured":"Bjorner JB Brett JH Meincke HH Kolotkin RL The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF-36: 3-year data Diabetologia 2016 S330"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0022|cit22","first-page":"A565","article-title":"Liraglutide 3.0 mg improves health utilities in weight management compared with placebo","volume":"64","author":"Bjorner","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0023|cit23","first-page":"S310","article-title":"Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks","volume":"58","author":"Bluher","year":"2015","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0024|cit24","unstructured":"EudraCT 2008-001049-24 Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-001049-24\/IE"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0025|cit25","first-page":"S368","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management in overweight\/obese adults: the SCALE obesity and prediabetes trial","volume":"57","author":"Fujioka","year":"2014","journal-title":"Diabetologia"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0026|cit26","first-page":"41","article-title":"Liraglutide 3.0 mg: weight-loss dependent and independent effects","volume":"8","author":"Gaal","year":"2015","journal-title":"Obesity Facts"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cob.12146","article-title":"Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management","volume":"6","author":"Kolotkin","year":"2016","journal-title":"Clinical Obesity"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/j.jval.2015.09.1991","article-title":"Impact of weight loss on patient-reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&E) programme","volume":"18","author":"Kolotkin","year":"2015","journal-title":"Value in Health"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0029|cit29","first-page":"210","article-title":"Additional analyses of the weight-lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial","volume":"8","author":"Krempf","year":"2015","journal-title":"Obesity Facts"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0030|cit30","first-page":"S368","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight\/obese adults: the SCALE obesity and prediabetes randomised trial","volume":"57","author":"Krempf","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0031|cit31","first-page":"OR07","article-title":"Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double-blind, placebo-controlled 56-week scale obesity and prediabetes trial","author":"Lau","year":"2015","journal-title":"Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5-8; San Diego (CA)"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0032|cit32","first-page":"185","article-title":"Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double-blind, placebo controlled, 56-week trial","volume":"8","author":"Lau","year":"2015","journal-title":"Obesity Facts"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0033|cit33","first-page":"S48","article-title":"Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial","volume":"39","author":"Lau","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0034|cit34","first-page":"S48","article-title":"Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight\/obesity: the SCALE obesity and prediabetes randomised trial","volume":"39","author":"Lau","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0035|cit35","first-page":"S358","article-title":"Liraglutide 3.0 mg improves insulin secretion and action in overweight\/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial","volume":"57","author":"Lau","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0036|cit36","first-page":"S338","article-title":"Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial","volume":"57","author":"Roux","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0037|cit37","first-page":"S311","article-title":"The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme","volume":"58","author":"Roux","year":"2015","journal-title":"Diabetologia"},{"issue":"10077","key":"10.1002\/14651858.CD012204.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Roux","year":"2017","journal-title":"Lancet"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jcjd.2015.01.142","article-title":"Liraglutide 3.0 mg reduces body weight and improves health-related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double-blind, placebo-controlled, 56-week trial","volume":"39","author":"Liutkus","year":"2015","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0040|cit40","unstructured":"Madsbad S Lieberman G Skjoth TV Lilleore SK De Fronzo RA Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial Diabetologia 2016 540 1"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0041|cit41","unstructured":"NCT01272219 Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE\u2122 - obesity and pre-diabetes clinicaltrials.gov\/ct2\/show\/NCT01272219"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0042|cit42","unstructured":"NN8022-1839 Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE\u2122 - obesity and pre-diabetes www.novonordisk-trials.com\/Website\/pdf\/registry\/nn80221839.pdf"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0044|cit44","first-page":"S37","article-title":"Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight\/obese adults: the SCALE obesity and prediabetes trial","volume":"57","author":"Pi-Sunyer","year":"2014","journal-title":"Diabetologia"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.orcp.2014.10.210","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double-blind and placebo-controlled trial","volume":"8","author":"Proietto","year":"2014","journal-title":"Obesity Research and Clinical Practice"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0046|cit46","first-page":"71","article-title":"In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre-diabetes trial","volume":"32","author":"Wilding","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0047|cit47","first-page":"70","article-title":"Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial","volume":"32","author":"Wilding","year":"2015","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.12639","article-title":"Exposure-response analyses of liraglutide 3.0 mg for weight management","volume":"18","author":"Wilding","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0049|cit49","first-page":"A568","article-title":"Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo","volume":"64","author":"Wilding","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.orcp.2014.10.211","article-title":"Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 56-week trial","volume":"8","author":"Wittert","year":"2014","journal-title":"Obesity Research and Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD012204.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"e12610","DOI":"10.14814\/phy2.12610","article-title":"Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study","volume":"3","author":"Acosta","year":"2015","journal-title":"Physiological Reports"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0052|cit52","unstructured":"ACTRN12615001029583 Does exenatide improve post prandial glycaemic control in young people with cystic fibrosis related diabetes or impaired glucose tolerance? www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=369121"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0053|cit53","unstructured":"Almeda-Valdes P Cuevas-Ramos D Brito-Cordova G Gomez-Perez FJ Treatment with sitagliptin phosphate in patients with symptomatic reactive hypoglycemia. A randomized, placebo-controlled, double-blinded, clinical trial 94th Annual Meeting and Expo; 2012 23-26 Jun; Houston (TX) 2012 SUN 209"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0054|cit54","unstructured":"NCT00847080 Treatment with sitagliptin for reactive hypoglycemia secondary to dysinsulinism clinicaltrials.gov\/ct2\/show\/NCT00847080"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1507\/endocrj.EJ13-0399","article-title":"Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels","volume":"61","author":"Aoki","year":"2014","journal-title":"Endocrine Journal"},{"issue":"8","key":"10.1002\/14651858.CD012204.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1507\/endocrj.K10E-103","article-title":"Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men","volume":"57","author":"Aoki","year":"2010","journal-title":"Endocrine Journal"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0057|cit57","unstructured":"UMIN000010481 Effect of miglitol and vildagliptin on gastrointestinal hormone upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000012252&language=E"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4158\/EP11194.OR","article-title":"Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta-cell dysfunction","volume":"18","author":"Armato","year":"2012","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0059|cit59","unstructured":"EUCTR2007-003963-31-SE BEGAMI www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-003963-31\/SE"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/joim.12032","article-title":"Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities - the BEGAMI study","volume":"273","author":"Hage","year":"2013","journal-title":"Journal of Internal Medicine"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0061|cit61","first-page":"793","article-title":"The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations","volume":"34","author":"Hage","year":"2013","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1479164114533355","article-title":"The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study","volume":"11","author":"Hage","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0063|cit63","unstructured":"NCT00627744 Beta-cell function in glucose abnormalities and acute myocardial infarction (BEGAMI) clinicaltrials.gov\/ct2\/show\/NCT00627744"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1210\/jc.2015-1531","article-title":"Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance","volume":"100","author":"Best","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2265.2009.03764.x","article-title":"The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose","volume":"73","author":"Bock","year":"2010","journal-title":"Clinical Endocrinology"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0066|cit66","first-page":"A447","article-title":"Estimation of GLP-1 induced potentiation of insulin secretion from an oral model","volume":"60","author":"Micheletto","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0067|cit67","unstructured":"NCT00364377 Incretins in impaired fasting glucose clinicaltrials.gov\/ct2\/show\/NCT00364377"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0068|cit68","first-page":"S313","article-title":"Sitagliptin effects on triglyceride and free fatty acid metabolism","volume":"52","author":"Nelson","year":"2009","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD012204.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.2337\/db14-1718","article-title":"Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system","volume":"64","author":"Daniele","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0071|cit71","first-page":"S37","article-title":"Effect of exenatide on postprandial cerebral and liver glucose metabolism: a double-blind randomised clinical trial","volume":"57","author":"Daniele","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0072|cit72","first-page":"A85","article-title":"Exenatide affects the distribution of cerebral postprandial glucose uptake: a double-blind, randomized clinical trial","volume":"63","author":"Daniele","year":"2014","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0073|cit73","unstructured":"NCT01588418 Effect of exenatide on brain, adipose tissue, pancreas, and liver function clinicaltrials.gov\/ct2\/show\/NCT01588418"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/dc11-0931","article-title":"Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes","volume":"35","author":"Dushay","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0075|cit75","unstructured":"NCT00456885 The effect of exenatide on weight and hunger in obese, healthy women clinicaltrials.gov\/ct2\/show\/NCT00456885"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0076|cit76","unstructured":"EudraCT 2011-005980-26 Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke - a multicenter, randomized, open-label phase II trial www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005980-26\/NL"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13063-015-0882-z","article-title":"Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial","volume":"16","author":"Osei","year":"2015","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0078|cit78","unstructured":"EudraCT 2013-001240-64 Effect of intact GLP-1 (7-36) and GLP-1 metabolite (9-36) on coronary microvascular function in adults with prediabetes www.clinicaltrialsregister.eu\/ctr-search\/search?query=2013-001240-64"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0079|cit79","unstructured":"Gonzalez-Ortiz M Perez-Rubio KG Martinezabundis E Lixisenatide vs. exenatide on metabolic control, insulin secretion, and insulin sensitivity in impaired glucose tolerance patients Diabetes 2015 A297"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0080|cit80","unstructured":"Effect of exenatide, sitagliptin or glimepiride on functional \u03b2-cell mass clinicaltrials.gov\/ct2\/show\/NCT00775684"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Gudipaty L Fuller C Rosenfeld N Rickels MR No effect of exenatide or sitagliptin therapy on beta-cell secretory capacity in early type 2 diabetes Diabetes 2013 A288","DOI":"10.2337\/dc14-0398"},{"issue":"9","key":"10.1002\/14651858.CD012204.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc14-0398","article-title":"Effect of exenatide, sitagliptin, or glimepiride on beta-cell secretory capacity in early type 2 diabetes","volume":"37","author":"Gudipaty","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amjcard.2014.04.050","article-title":"Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus","volume":"114","author":"Ishikawa","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD012204.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/dom.12507","article-title":"Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0085|cit85","unstructured":"NCT01405911 Dose response finding study of MK-0431\/ONO-5435 in Japanese subjects with impaired glucose tolerance (MK-0431-105) clinicaltrials.gov\/ct2\/show\/NCT01405911"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db14-0976","article-title":"Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans","volume":"64","author":"Koska","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0087|cit87","unstructured":"NCT01181986 The study of exenatide action on vessel function in type 2 diabetes and prediabetes clinicaltrials.gov\/ct2\/show\/NCT01181986"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e004227","DOI":"10.1136\/bmjopen-2013-004227","article-title":"Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial","volume":"4","author":"Larsen","year":"2014","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0089|cit89","unstructured":"NCT00101712 Efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia clinicaltrials.gov\/ct2\/show\/NCT00101712"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0090|cit90","unstructured":"NCT00198146 Prevention of Diabetes Progression Trial (PDPT) clinicaltrials.gov\/ct2\/show\/NCT00198146"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0091|cit91","unstructured":"NCT00721552 Sitagliptin prophylaxis for glucocorticoid-induced impairment of glucose metabolism in males with the metabolic syndrome (SPHINX) clinicaltrials.gov\/ct2\/show\/NCT00721552"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0092|cit92","unstructured":"NCT00845182 Effect of pioglitazone and exenatide on body weight and beta cell function (PIO-EX) clinicaltrials.gov\/ct2\/show\/study\/NCT00845182"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0093|cit93","unstructured":"NCT00845559 The effects of exenatide on post-meal sugar peaks and vascular health in obese\/pre-diabetic young adults clinicaltrials.gov\/ct2\/show\/NCT00845559"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0094|cit94","unstructured":"NCT00886626 GLP-1 therapy for weight loss and improved glucose tolerance in obese children clinicaltrials.gov\/ct2\/show\/NCT00886626"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0095|cit95","unstructured":"NCT00961363 Effect of sitagliptin in impaired glucose tolerance clinicaltrials.gov\/ct2\/show\/NCT00961363"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0096|cit96","unstructured":"NCT01006018 DPP-4 Inhibition and TZD for DM Prevention (DInT DM) clinicaltrials.gov\/ct2\/show\/NCT01006018"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0097|cit97","unstructured":"NCT01018602 PINGUIN (Postpartum Intervention in Women with Gestational Diabetes Using Insulin) clinicaltrials.gov\/ct2\/show\/NCT01018602"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0098|cit98","unstructured":"NCT01038648 Sitagliptin in Prevention of Type 2 Diabetes Mellitus (SITAGLIPTIN) clinicaltrials.gov\/ct2\/show\/NCT01038648"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0099|cit99","unstructured":"NCT01054118 A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of JNJ-38431055, sitagliptin, and co-administration of JNJ-38431055 and sitagliptin clinicaltrials.gov\/ct2\/show\/NCT01054118"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0100|cit100","unstructured":"NCT01122641 The vascular effects of vildagliptin in insulin resistant individuals clinicaltrials.gov\/ct2\/show\/NCT01122641"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0101|cit101","unstructured":"NCT01346254 Glucose control in pre-diabetic renal transplant patients (GCPD) clinicaltrials.gov\/ct2\/show\/NCT01346254"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0102|cit102","unstructured":"NCT01472640 The effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes mellitus clinicaltrials.gov\/ct2\/show\/NCT01472640"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0103|cit103","unstructured":"NCT01845259 Does a GLP-1 receptor agonist change glucose tolerance in antipsychotic-treated patients? (GREAT) clinicaltrials.gov\/ct2\/show\/NCT01845259"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0104|cit104","unstructured":"NCT01970462 Use of sitagliptin for stress hyperglycemia or mild diabetes following cardiac surgery clinicaltrials.gov\/ct2\/show\/NCT01970462"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0105|cit105","unstructured":"NCT02016846 Liraglutide efficacy on glucocorticoid induced hyperglycemia in patients high risk for diabetes clinicaltrials.gov\/ct2\/show\/NCT02016846"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0106|cit106","unstructured":"NCT02022007 Saxagliptin + metformin compared to saxagliptin or metformin monotherapy in PCOS women Wwith impaired glucose homeostasis (BMS-AZPCOS) clinicaltrials.gov\/ct2\/show\/NCT02022007"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0107|cit107","unstructured":"2014-001778-32\/DK The LiRA2 study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001778-32\/DK"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0108|cit108","unstructured":"NCT02284230 The effect of liraglutide in patients with prediabetes and kidney failure (LiRA2) clinicaltrials.gov\/ct2\/show\/NCT02284230"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0109|cit109","unstructured":"NCT02446834 Research of intensive lifestyle Intervention for PCOS patients with IGT clinicaltrials.gov\/ct2\/show\/NCT02446834"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db14-0976","article-title":"Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans","volume":"64","author":"Koska","year":"2015","journal-title":"Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2337\/dc09-1961","article-title":"Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes","volume":"33","author":"Koska","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0112|cit112","first-page":"P","article-title":"Acute administration of exenatide improves endothelial function following a high-fat meal","volume":"58","author":"Mullin","year":"2009","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0113|cit113","unstructured":"Schwartz EA Koska J Mullin MP Schwenke DC Reaven PD Effects of acute exenatide administration on postprandial lipids and lipoproteins in individuals with impaired glucose metabolism Diabetes 2009 375 OR"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/clp.13.46","article-title":"Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes","volume":"8","author":"Aramaki","year":"2013","journal-title":"Clinical Lipidology"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0117|cit116","first-page":"A280","article-title":"Alogliptin ameliorates dyslipidemia and LDL-size in patients with IGT or type 2 diabetes: comparing alogliptin and voglibose","volume":"60","author":"Tsuchiya","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0118|cit117","first-page":"A595","article-title":"Alogliptin decreases liver fat content in patients with IGT or type Q2 DM: comparing alogliptin and voglibose","volume":"60","author":"Tsuchiya","year":"2011","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0116|cit118","first-page":"A297","article-title":"DPP4 inhibition ameliorates intramuscular fat content in patients with IGT or type 2 DM: comparing alogliptin and voglibose","volume":"62","author":"Tsuchiya","year":"2013","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0119|cit119","unstructured":"UMIN000006197 Therapeutic efficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) in impaired glucose tolerance (IGT): a pilot study upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&recptno=R000007311&type=summary&language=E"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0120|cit120","unstructured":"UMIN000014249 Efficacy and safety of combination therapy with GLP-1 analog lixisenatide and long-acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000016598&language=E"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0121|cit121","unstructured":"NCT00312130 A study to evaluate the effects of vildagliptin on the insulin response to glucose in subjects with pre-diabetes clinicaltrials.gov\/ct2\/show\/NCT00312130"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2337\/dc07-1441","article-title":"The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose","volume":"31","author":"Utzschneider","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"International Journal of Obesity (2005)"},{"issue":"9701","key":"10.1002\/14651858.CD012204.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0126|cit126","unstructured":"EudraCT 2006-004481-13 Effect of liraglutide on body weight in obese subjects without diabetes. A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004481-13\/DK"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0127|cit127","first-page":"30","article-title":"Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non-diabetic adults over two years","volume":"3","author":"Finer","year":"2011","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0128|cit128","article-title":"Liraglutide, a once-daily human GLP-1 analog, reverses indices of prediabetes in obese subjects: a randomized placebo-controlled 20-week trial","volume":"58","author":"Finer","year":"2009","journal-title":"Diabetes"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0129|cit129","first-page":"S11","article-title":"Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial","volume":"52","author":"Finer","year":"2009","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0131|cit131","unstructured":"NCT00422058 The effect of liraglutide on body weight in obese subjects without diabetes clinicaltrials.gov\/ct2\/show\/NCT00422058"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0132|cit132","unstructured":"NN8022-1807 The effect of liraglutide on body weight in obese subjects without diabetes www.novonordisk-trials.com\/Website\/pdf\/registry\/nn80221807.pdf"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0133|cit133","first-page":"S56","article-title":"Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non-diabetic adults: a 2-year randomized trial","volume":"18","author":"Niskanen","year":"2010","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0134|cit134","unstructured":"Synopsis NN8022-1807 Effect of liraglutide on body weight in obese subjects without diabetes. A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period novonordisk-trials.com\/website\/pdf\/registry\/bin_20110928-123116-617.pdf"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0135|cit135","unstructured":"NCT01521312 Acute and chronic effects of saxagliptin (ACCES) clinicaltrials.gov\/ct2\/show\/NCT01521312"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0136|cit136","unstructured":"NCT01960205 Effect of saxagliptin on pre-diabetes mellitus and obesity clinicaltrials.gov\/ct2\/show\/NCT01960205"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0137|cit137","unstructured":"EudraCT: 2014-003532-39 The effect of the diabetes medication sitagliptin on brown fat and whole-body metabolism in men with overweight and impaired glucose tolerance (or 'pre-diabetes') www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-003532-39\/NL"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0138|cit138","unstructured":"NCT02294084 Sitagliptin and brown adipose tissue (Sita01) clinicaltrials.gov\/ct2\/show\/NCT02294084"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0139|cit139","first-page":"S375","article-title":"Effects of liraglutide vs lifestyle changes on subcutaneous and visceral fat, liver steatosis, insulin sensitivity and beta cell function after comparable weight loss","volume":"58","author":"Santilli","year":"2015","journal-title":"Diabetologia"},{"issue":"0","key":"10.1002\/14651858.CD012204.pub2-BIB0140|cit140","first-page":"473","article-title":"Liraglutide is more effective than lifestyle changes in modulating subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta-cell function after comparable weight loss","volume":"36","author":"Santilli","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0141|cit141","first-page":"A287","article-title":"Effects of liraglutide or lifestyle counseling on subcutaneous and visceral fat distribution, liver fat content, insulin sensitivity, and beta-cell performance","volume":"64","author":"Santilli","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0142|cit142","first-page":"124","article-title":"Diet-induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight\/obese adults in the SCALEtm maintenance 56-week randomised trial","volume":"5","author":"Hollander","year":"2013","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0143|cit143","first-page":"206","article-title":"Effect of diet-induced weight loss and subsequent addition of liraglutide 3.0 MG on impaired fasting glucose in overweight\/obese adults in the SCALEtm maintenance 56-week phase 3 randomised trial","volume":"5","author":"Klein","year":"2012","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0144|cit144","unstructured":"Klein S Aronne LJ Hollander P Niswender K Woo V Hale PM Effect of liraglutide on cardiovascular (CV) risk factors in adults without diabetes after diet-induced weight loss: the SCALE 56-week randomized study Obesity (Silver Spring, Md.) 2011 S177"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0145|cit145","unstructured":"NCT00781937 Comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE - maintenance clinicaltrials.gov\/show\/NCT00781937"},{"issue":"11","key":"10.1002\/14651858.CD012204.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"International Journal of Obesity"},{"issue":"8","key":"10.1002\/14651858.CD012204.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0148|cit148","unstructured":"NCT01557166 Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE\u2122 - sleep apnoea clinicaltrials.gov\/ct2\/show\/NCT01272232"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0149|cit149","unstructured":"NN8022-3970 Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE\u2122 - sleep apnoea novonordisk-trials.com\/Website\/pdf\/registry\/nn80223970.pdf"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0152|cit150","unstructured":"Unpublished protocol Provided by the investigators"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0150|cit151","unstructured":"EUCTR2013-000418-39-AT Early prevention of diabetes complications in people with hyperglycaemia in Europe - e-PREDICE apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000418-39-AT"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0151|cit152","unstructured":"EudraCT 2013-000418-39 Early prevention of diabetes complications in people with hyperglycaemia in Europe www.clinicaltrialsregister.eu\/ctr-search\/search?query=2013-000418-39"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0153|cit153","unstructured":"ePRECIDE The project www.epredice.eu\/en\/the-project"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.2196\/resprot.5073","article-title":"Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes - a randomized, double-blind, double-arm, multicenter clinical trial: protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) study","volume":"5","author":"Naidoo","year":"2016","journal-title":"JMIR Research Protocols"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0155|cit155","unstructured":"NCT01234649 Combined liraglutide and metformin therapy in women with previous gestational diabetes mellitus (GDM) clinicaltrials.gov\/ct2\/show\/NCT01234649"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0156|cit156","unstructured":"NCT01336322 Metformin and sitagliptin in women with previous gestational diabetes clinicaltrials.gov\/ct2\/show\/NCT01336322"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0157|cit157","unstructured":"NCT01548651 Effect of saxagliptin treatment on myocardial fat content, and monocyte inflammation clinicaltrials.gov\/ct2\/show\/NCT01548651"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0158|cit158","unstructured":"NCT01779362 RISE adult medication study (RISE Adult) clinicaltrials.gov\/ct2\/show\/NCT01779362"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2337\/dc13-1879","article-title":"Restoring Insulin Secretion (RISE): design of studies of beta-cell preservation in prediabetes and early type 2 diabetes across the life span","volume":"37","author":"RISE Consortium","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0160|cit160","unstructured":"EudraCT 2012-001371-37 GDM-TREAT www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-001371-37\/DK"},{"issue":"10","key":"10.1002\/14651858.CD012204.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"e003834","DOI":"10.1136\/bmjopen-2013-003834","article-title":"The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial","volume":"3","author":"Foghsgaard","year":"2013","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0162|cit162","unstructured":"NCT01795248 The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous pregnancy-induced diabetes clinicaltrials.gov\/ct2\/show\/NCT01795248"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0163|cit163","unstructured":"NCT01856907 Sitagliptin + metformin compared to metformin monotherapy and placebo in women with a recent GDM clinicaltrials.gov\/ct2\/show\/NCT01856907"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0164|cit164","unstructured":"NCT02104739 Effects of antidiabetic medications on the postprandial state in prediabetes clinicaltrials.gov\/ct2\/show\/NCT02104739"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0165|cit165","unstructured":"NCT02140983 Effects of liraglutide on hippocampal structure and function in aging adults with prediabetes (LGT) clinicaltrials.gov\/ct2\/show\/NCT02140983"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0166|cit166","unstructured":"NCT02488057 Improving beta cell function in Mexican American women with prediabetes clinicaltrials.gov\/ct2\/show\/NCT02488057"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0167|cit167","unstructured":"NCT02576288 Sitagliptin effects on arterial vasculature and inflammation in obesity (SAVORO) clinicaltrials.gov\/ct2\/show\/NCT02576288"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0168|cit168","unstructured":"NCT02847403 Long-acting exenatide and cognitive decline in dysglycemic patients (DRINN) clinicaltrials.gov\/show\/NCT02847403"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0169|cit169","unstructured":"NCT02969798 Pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) clinicaltrials.gov\/show\/NCT02969798"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0170|cit170","unstructured":"NCT03004612 Effect of linagliptin + metformin vs metformin alone in patients with prediabetes (PRELLIM) clinicaltrials.gov\/show\/NCT03004612"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0171|cit171","unstructured":"UMIN000008620 The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&recptno=R000010058&type=summary&language=E"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"20","author":"The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"1997","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012204.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.26.2007.S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"26","author":"Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012204.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes - 2008","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012204.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes - 2014","volume":"37 Suppl 1","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012204.pub2-BIB0178|cit178","first-page":"S1","article-title":"Standards of medical care in diabetes - 2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012204.pub2-BIB0179|cit179","first-page":"S4","article-title":"Standards of medical care in diabetes - 2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1345\/aph.1E081","article-title":"Pharmacologic prevention or delay of type 2 diabetes mellitus","volume":"39","author":"Anderson","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/pon.3205","article-title":"Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures","volume":"22","author":"Bell","year":"2013","journal-title":"Psycho-oncology"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0182|cit182","unstructured":"Bhardwaj A Agarwal V Phung OJ Baker WL Tongbram V Coleman CI Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance? 70th Scientific Sessions of the American Diabetes Association; 2010 25-29 June; Orlando (FL) 2010"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jval.2013.06.022","article-title":"Benchmarks for interpretation of score differences on the SF-36 health survey for patients with diabetes","volume":"16","author":"Bjorner","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2014.56.7503","article-title":"Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial","volume":"32","author":"Boutron","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0187|cit187","unstructured":"Centers for Disease Control and Prevention 2014 National Diabetes Statistics Report www.cdc.gov\/diabetes\/data\/statistics\/2014statisticsreport.html"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.metabol.2005.10.003","article-title":"The utility of fasting glucose for detection of prediabetes","volume":"55","author":"Cheng","year":"2006","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0189|cit189","unstructured":"Search terms: prediabetes drugs clinicaltrials.gov\/ct2\/results?term=prediabetes+drugs&Search=Search"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Research Synthesis Methods"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01225454","article-title":"The incretin concept today","volume":"16","author":"Creutzfeldt","year":"1979","journal-title":"Diabetologia"},{"issue":"11","key":"10.1002\/14651858.CD012204.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14740338.2014.955013","article-title":"Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?","volume":"13","author":"Heer","year":"2014","journal-title":"Expert Opinion on Drug Safety"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"12","key":"10.1002\/14651858.CD012204.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"9702","key":"10.1002\/14651858.CD012204.pub2-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2337\/dc13-2195","article-title":"Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis","volume":"37","author":"Dunkley","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD012204.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs - FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2288-14-49","article-title":"Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study","volume":"14","author":"Egbewale","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40256-016-0208-x","article-title":"Cardiovascular safety of dipeptidyl-peptidase IV inhibitors: a meta-analysis of placebo-controlled randomized trials","volume":"17","author":"Elgendy","year":"2017","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0200|cit200","unstructured":"European Medicines Agency Assessment Report. Saxenda. International non-proprietary name: liraglutide www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003780\/WC500185788.pdf"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0201|cit201","unstructured":"US Food Drug Administration Drug approval package: Byetta (exenatide) injection www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_ByettaTOC.cfm"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0202|cit202","unstructured":"US Food Drug Administration FDA approves new treatment for diabetes www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108770"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0203|cit203","unstructured":"US Food Drug Administration Saxenda Injection (Liraglutide [rDNA origin]) www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206321Orig1s000TOC.cfm"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MAJ.0000000000000223","article-title":"Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice","volume":"348","author":"Gosmanov","year":"2014","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0205|cit205","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2015"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012106.pub2","article-title":"Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0207|cit207","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012204.pub2-BIB0208|cit208","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012151.pub2","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012204.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society. Series A, (Statistics in Society)"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0212|cit212","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD012204.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/sim.4088","article-title":"Sequential methods for random-effects meta-analysis","volume":"30","author":"Higgins","year":"2011","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"issue":"6410","key":"10.1002\/14651858.CD012204.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/361362a0","article-title":"Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)","volume":"361","author":"Holz","year":"1993","journal-title":"Nature"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1741826711421687","article-title":"Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials","volume":"18","author":"Hopper","year":"2011","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0219|cit219","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice 1997 CFR & ICH Guidelines","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0220|cit220","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2015"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMcp1103643","article-title":"Clinical practice. Diagnosis of diabetes","volume":"367","author":"Inzucchi","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.2337\/diabetes.51.7.2170","article-title":"Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S","volume":"51","author":"Jensen","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"issue":"10077","key":"10.1002\/14651858.CD012204.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Lle Roux","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0229|cit229","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2009.1242","article-title":"Comparison of registered and published primary outcomes in randomized controlled trials","volume":"302","author":"Mathieu","year":"2009","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00125-013-2902-4","article-title":"Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis","volume":"56","author":"Morris","year":"2013","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0233|cit233","doi-asserted-by":"crossref","unstructured":"Nagel AK Ahmed-Sarwar N Werner PM Cipriano GC van Manen RP Brown JE Dipeptidyl peptidase-4 inhibitor-associated pancreatic carcinoma: a review of the FAERS database Annals of Pharmacotherapy 2015 27 31","DOI":"10.1177\/1060028015610123"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0235|cit235","unstructured":"NCT02161588 A trial to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy male Japanese and Caucasian subjects clinicaltrials.gov\/ct2\/show\/NCT02161588"},{"issue":"12","key":"10.1002\/14651858.CD012204.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diab.28.12.1039","article-title":"Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group","volume":"28","author":"National Diabetes Data Group","year":"1979","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/endo-123-4-2009","article-title":"Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach","volume":"123","author":"Orskov","year":"1988","journal-title":"Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1345\/aph.1Q554","article-title":"Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis","volume":"46","author":"Phung","year":"2012","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD012204.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"580-93; discuss","DOI":"10.1016\/S0197-2456(97)00051-2","article-title":"Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis","volume":"18","author":"Pogue","year":"1997","journal-title":"Controlled Clinical Trials"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.metabol.2003.11.011","article-title":"Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance","volume":"53","author":"Rask","year":"2004","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","article-title":"Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials","volume":"43","author":"Rehman","year":"2017","journal-title":"Diabetes & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2337\/diaclin.31.4.148","article-title":"Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care","volume":"31","author":"Reid","year":"2014","journal-title":"Clinical Diabetes"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0243|cit243","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"16","key":"10.1002\/14651858.CD012204.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/sim.5726","article-title":"Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data","volume":"32","author":"Riley","year":"2013","journal-title":"Statistics in Medicine"},{"issue":"14","key":"10.1002\/14651858.CD012204.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012204.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-154-5-201103010-00004","article-title":"Racial differences in glycemic markers: a cross-sectional analysis of community-based data","volume":"154","author":"Selvin","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012204.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets","volume":"19","author":"Siddiqui","year":"2009","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD012204.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"18","key":"10.1002\/14651858.CD012204.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0252|cit252","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005061.pub2","article-title":"Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose","author":"Laar","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/epirev\/mxr002","article-title":"Predisease: when does it make sense?","volume":"33","author":"Viera","year":"2011","journal-title":"Epidemiologic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012204.pub2-BIB0254|cit254","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000009.pub4","article-title":"Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate","author":"Vist","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD012204.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0257|cit257","volume-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus","author":"World Health Organization","year":"1999"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0258|cit258","unstructured":"World Health Organization\/International Diabetes Federation Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdf 2006"},{"issue":"4","key":"10.1002\/14651858.CD012204.pub2-BIB0259|cit259","first-page":"451","article-title":"Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"1","key":"10.1002\/14651858.CD012204.pub2-BIB0260|cit260","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"7644","key":"10.1002\/14651858.CD012204.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012204.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"g4485","DOI":"10.1136\/bmj.g4485","article-title":"The epidemic of pre-diabetes: the medicine and the politics","volume":"349","author":"Yudkin","year":"2014","journal-title":"BMJ"},{"issue":"9982","key":"10.1002\/14651858.CD012204.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012204.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T14:21:00Z","timestamp":1651760460000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012204.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,10]]},"references-count":263,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012204.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,10]]}}}